
Please try another search
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Name | Age | Since | Title |
---|---|---|---|
Cuong Viet Do | 56 | 2016 | President, CEO & Director |
James Lang | 58 | 2016 | Independent Chairman |
Michael Edward Sherman | 64 | 2017 | Independent Director |
Sigmund Aronson Rogich | 81 | 2020 | Independent Director |
Justina Omokhua | - | 2025 | Member of Corporate Advisory Board |
Kush Saxena | - | 2025 | Member of Corporate Advisory Board |
Tim Gardner | - | 2025 | Member of Corporate Advisory Board |
Gregory Nguyen | - | 2025 | Member of Corporate Advisory Board |
Ugochi Owo | - | 2025 | Chair of Corporate Advisory Board |
Zaldy Tan | - | 2025 | Member of Corporate Advisory Board |
Casey Woo | - | 2025 | Member of Corporate Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review